Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vor Biopharma Inc (VOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: VOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $0.57
1 Year Target Price $0.57
| 0 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.44% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 132.46M USD | Price to earnings Ratio - | 1Y Target Price 0.57 |
Price to earnings Ratio - | 1Y Target Price 0.57 | ||
Volume (30-day avg) 5 | Beta -0.51 | 52 Weeks Range 0.13 - 1.80 | Updated Date 06/30/2025 |
52 Weeks Range 0.13 - 1.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.25% | Return on Equity (TTM) -125.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 106952876 | Price to Sales(TTM) - |
Enterprise Value 106952876 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.09 | Shares Outstanding 124960000 | Shares Floating 39043602 |
Shares Outstanding 124960000 | Shares Floating 39043602 | ||
Percent Insiders 31.89 | Percent Institutions 48.76 |
Analyst Ratings
Rating 3 | Target Price 0.57 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vor Biopharma Inc
Company Overview
History and Background
Vor Biopharma Inc. was founded in 2016, based on the research of Dr. Siddhartha Mukherjee and Dr. Peter Sorger, to develop engineered hematopoietic stem cells (eHSCs) to treat hematological malignancies. Their approach is to engineer stem cells to resist chemotherapy, thus protecting the body's immune system during treatment. Milestones include preclinical and clinical trial progress, securing funding, and expanding their pipeline.
Core Business Areas
- Engineered Hematopoietic Stem Cell (eHSC) Therapy: Developing eHSCs resistant to chemotherapy, allowing for higher, more effective doses to treat cancer.
Leadership and Structure
Robert Pietrusko (CEO), Tia Bushman (Chief Financial Officer). The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- VOR33: Vor's lead product candidate, VOR33, is an engineered hematopoietic stem cell (eHSC) product candidate designed to enable targeted cancer therapy while protecting healthy cells from chemotherapy damage. Currently in clinical trials for Acute Myeloid Leukemia (AML). Competitors include standard chemotherapy regimens and alternative stem cell transplant methods; direct market share data not readily available. Revenue is currently $0 as the drug is not yet approved.
Market Dynamics
Industry Overview
The industry focuses on novel cancer therapies, particularly in hematological malignancies. There is a high unmet need for more effective and less toxic treatments.
Positioning
Vor Biopharma is positioned as an innovator in engineered stem cell therapy, aiming to improve cancer treatment outcomes. Their advantage lies in their eHSC technology platform.
Total Addressable Market (TAM)
The TAM for hematological malignancy treatments is estimated to be in the tens of billions of dollars. Vor Biopharma is targeting a segment of this market with their eHSC technology.
Upturn SWOT Analysis
Strengths
- Novel eHSC technology platform
- Strong scientific foundation
- Experienced leadership team
- Potential for improved treatment outcomes
Weaknesses
- Early stage clinical development
- High research and development costs
- Dependence on successful clinical trial results
- Limited commercial infrastructure
Opportunities
- Expansion into new indications
- Partnerships with pharmaceutical companies
- Advancements in stem cell engineering
- Positive clinical trial data driving market adoption
Threats
- Competition from established cancer therapies
- Regulatory hurdles and approval timelines
- Clinical trial failures
- Technological advancements rendering their technology obsolete
Competitors and Market Share
Key Competitors
- BMY
- GILD
- CLVS
Competitive Landscape
Vor has the advantage of using eHSC while it also carries a disadvantage as the product is still in clinical trials. Vor Biopharma competes with established pharmaceutical companies developing cancer therapies. Their competitive advantage is their eHSC platform, if proven effective.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by R&D investments and clinical trial progress, not revenue.
Future Projections: Future growth hinges on successful clinical trial data, regulatory approvals, and commercialization efforts. Analyst estimates depend on these outcomes.
Recent Initiatives: Focus on advancing VOR33 through clinical trials, exploring new eHSC applications, and seeking potential partnerships.
Summary
Vor Biopharma is a development-stage company with a promising eHSC platform targeting hematological malignancies. Their strength lies in their innovative technology, but they face significant risks related to clinical trials and regulatory approvals. Success depends on demonstrating clinical efficacy and safety. The company needs to ensure sufficient funding to support its R&D efforts and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Vor Biopharma Inc. Investor Relations
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on available resources and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vor Biopharma Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-02-05 | Chairman & CEO Dr. Jean-Paul Kress M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.vorbio.com |
Full time employees 159 | Website https://www.vorbio.com | ||
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.